Mitomycin
Jelmyto, Mitomycin, Mitosol (mitomycin) is a small molecule pharmaceutical. Mitomycin was first approved as Mutamycin on 1982-01-01. It is used to treat adenocarcinoma, colorectal neoplasms, pancreatic neoplasms, stomach neoplasms, and urinary bladder neoplasms in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Jelmyto, Mitomycin, Mitosol (discontinued: Mitomycin, Mitozytrex, Mutamycin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mitomycin
Tradename
Company
Number
Date
Products
MITOSOLMobius TherapeuticsN-022572 RX2012-02-07
1 products, RLD, RS
JELMYTOUroGen PharmaN-211728 RX2020-04-15
1 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
jelmytoNew Drug Application2024-10-14
mitomycinANDA2025-03-06
mitosolNew Drug Application2024-11-25
mutamycinANDA2025-03-12
Agency Specific
FDA
EMA
Expiration
Code
MITOMYCIN, JELMYTO, UROGEN PHARMA
2027-04-15ODE-289
Patent Expiration
Patent
Expires
Flag
FDA Information
Mitomycin, Jelmyto, Urogen Pharma
90400742031-01-20DP
99500692031-01-20DP
Mitomycin, Mitosol, Mobius Therap
96494282029-05-21U-2095
78062652029-02-01DP
95392412028-01-02DS, DPU-2095
81865112026-07-19DP
92050752026-07-19DP
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01D: Cytotoxic antibiotics and related substances
L01DC: Other cytotoxic antibiotics in atc
L01DC03: Mitomycin
HCPCS
Code
Description
J7315
Mitomycin, ophthalmic, 0.2 mg
J9280
Injection, mitomycin, 5 mg
J9281
Mitomycin pyelocalyceal instillation, 1 mg
Clinical
Clinical Trials
377 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Appendiceal neoplasmsD001063EFO_0003880C18.125310
AdenocarcinomaD0002302316
SarcomaD012509415
Esophageal stenosisD004940K22.2145
Gastrointestinal neoplasmsD005770C26.9234
Pleural neoplasmsD0109971113
Uterine neoplasmsD014594EFO_0003859C551113
SyndromeD013577112
Renal insufficiencyD051437N19112
BlisterD001768112
Show 28 more
Indications Phases 1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HydrophthalmosD006871EFO_1000968Q15.044
Lacrimal duct obstructionD00776722
Intraocular pressureD00742922
Pleural effusionD010996J9011
Gallbladder neoplasmsD005706EFO_0004606C2311
Corneal diseasesD003316H18.911
Iris diseasesD00749911
Deglutition disordersD003680R13.111
MucoceleD00907811
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.911
Show 15 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMitomycin
INNmitomycin
Description
Mitomycin C is a mitomycin. It has a role as an antineoplastic agent and an alkylating agent. It is a conjugate acid of a mitomycin C(1-).
Classification
Small molecule
Drug classantibiotics (Streptomyces strain)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
Identifiers
PDB
CAS-ID50-07-7
RxCUI
ChEMBL IDCHEMBL105
ChEBI ID27504
PubChem CID5746
DrugBankDB00305
UNII ID50SG953SK6 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
Jelmyto UroGen Pharma
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 49,142 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,283 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use